Selective PI3Kδ Inhibitors Isoform Discrimination
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PI3K inhibitors, such as wortmannin and LY294002, are non-specific, making it difficult to distinguish between different PI3K isoforms and understand their individual roles in cellular processes and diseases, particularly in inflammatory and autoimmune settings, where PI3Kδ plays a crucial role.
Innovation Solution
Development of selective compounds, including quinazolinone purine inhibitors like IC87114 and pyrazine derivatives, that specifically inhibit PI3Kδ activity with low potency against other PI3K isoforms, allowing for targeted modulation of PI3Kδ in diseases mediated by PI3Kδ dysfunction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-specific PI3K inhibitors (wortmannin, LY294002) are used, then PI3K activity is inhibited, but selectivity between different PI3K isoforms is lost
Solution Approach 1:
The patent applies local quality by designing inhibitors with specific molecular features that target particular PI3K isoforms. The compounds contain heteroaryl rings (pyrimidine, pyridine, triazole) at specific positions of the quinoline or quinoxaline core structure, creating localized interaction points that confer isoform-selectivity. This allows the inhibitor to maintain general PI3K binding capability while adding specific local features that discriminate between isoforms.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters of the inhibitor structure, including substituent types (halogens, alkyl groups, heteroaryl rings), substituent positions, and core structure variations (quinoline vs quinoxaline). These parameter modifications enable fine-tuning of isoform selectivity while preserving overall inhibitory activity against PI3K.
2Measurement precision
If selective PI3Kδ inhibitors are developed, then isoform selectivity is improved, but potential loss of activity against other PI3K isoforms occurs
Solution Approach 1:
The patent applies partial action by designing inhibitors that provide sufficient inhibition of PI3Kδ for therapeutic purposes without requiring complete inhibition of all PI3K isoforms. The compounds achieve selective PI3Kδ inhibition at clinically relevant concentrations, allowing adequate coverage of the primary target while accepting reduced activity against other isoforms. This partial selectivity approach balances efficacy with safety.
3Adaptability or versatility
If broad-spectrum PI3K inhibition is achieved, then coverage of multiple isoforms is improved, but ability to study individual isoform functions is reduced
Solution Approach 1:
The patent applies segmentation by dividing the PI3K inhibitor landscape into isoform-specific agents. The disclosed compounds represent a segmented approach where selective PI3Kδ inhibitors are developed alongside other isoform-selective agents. This segmentation enables researchers to use appropriate tools for studying specific isoform functions without the confounding effects of broad-spectrum inhibition.
Data Source
AI summary
Substituted bicyclic heteroaryls having the structure: (I) or any pharmaceutically-acceptable salt thereof, wherein: X1 is C(R9) or N; X2 is C(R10) or N; Y is N(R11), O or S; which are useful to inhibit the biological activity of human PI3Kd and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110d activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo- dysplastic syndrome (MDS) myeloproliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia ( T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.